arbekacin has been researched along with Hematologic Neoplasms in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatta, Y; Hirabayashi, Y; Hojo, A; Iriyama, N; Kobayashi, S; Kobayashi, Y; Kodaira, H; Kurita, D; Kusuda, M; Miura, K; Nakagawa, M; Ohtake, S; Sakagami, M; Takahashi, H; Takei, M; Uchino, Y | 1 |
1 trial(s) available for arbekacin and Hematologic Neoplasms
| Article | Year |
|---|---|
Clinical efficacy and safety of arbekacin for high-risk infections in patients with hematological malignancies.
Topics: Adult; Aged; Anti-Infective Agents; beta-Lactams; Dibekacin; Drug Monitoring; Drug Therapy, Combination; Febrile Neutropenia; Female; Fluoroquinolones; Hematologic Neoplasms; Humans; Infusions, Intravenous; Male; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Pneumonia, Bacterial; Staphylococcal Infections; Treatment Outcome | 2016 |